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Angiogenesis is a crucial requirement for malignant tumor growth, progression and metastasis. Tumor-
derived factors stimulate formation of new blood vessels which actively support tumor growth and
spread. Various of drugs have been applied to inhibit tumor angiogenesis. CPU-12, 4-chloro-N-(4-((2-(4-
methoxyphenyl)-5-methyloxazolo[5,4-d] pyrimidin-7-yl)amino)phenyl)benzamide, is a novel oxazolo
[5,4-d]pyrimidine derivative that showed potent activity in inhibiting VEGF-induced angiogenesis
in vitro and ex-vivo. In cell toxicity experiments, CPU-12 signiﬁcantly inhibited the human umbilical vein
endothelial cell (HUVEC) proliferation in a dose-dependent manner with a low IC50 value at
9.30 ± 1.24 mM. In vitro, CPU-12 remarkably inhibited HUVEC's migration, chemotactic invasion and
capillary-like tube formation in a dose-dependent manner. In ex-vivo, CPU-12 effectively inhibited new
microvessels sprouting from the rat aortic ring. In addition, the downstream signalings of vascular
endothelial growth factor receptor-2 (VEGFR-2), including the phosphorylation of PI3K, ERK1/2 and p38
MAPK, were effectively down-regulated by CPU-12. These evidences suggested that angiogenic response
via the induction of VEGFR through distinct signal transduction pathways regulating proliferation,
migration and tube formation of endothelial cells was signiﬁcantly inhibited by the novel small molecule
compound CPU-12 in vitro and ex-vivo. In conclusion, CPU-12 showed superior anti-angiogenic activity
in vitro.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Angiogenesis is a physiological process by which new blood
vessels sprouting from pre-existing vessels. Angiogenesis occurs
during several physiological and pathological conditions (1).
Although angiogenesis is essential for normal physiological pro-
cesses, it also plays a signiﬁcant role in the development of dis-
eases, including cancer (2), rheumatoid arthritis (3) and diabetic
retinopathy (4). Tumor vessels develop by sprouting from pre-
existing vessels and supply nutrient for tumor tissue, and hence6 2583271160.
yuyaoda@163.com (Y. Liu).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).most tumor growth and metastasis are angiogenesis-dependent
(5). Therefore, inhibition of tumor angiogenesis is one of the
promising strategies in the development of novel anticancer ther-
apy. The most vital players for angiogenesis are blood vessel
growth-promoting factors and inhibiting factors (6). There are
various molecular factors involved in angiogenesis. Among these,
members of vascular endothelial growth factor (VEGF) family have
a predominant role. VEGF promotes angiogenesis and remodels of
the vasculature by activation of vascular endothelial growth factor
receptor (VEGFR) and subsequently facilitates tumor growth (7).
VEGFR is a key protein tyrosine kinase receptor and locates on the
surface of endothelial cells. VEGFR-2 is thought to initiate intra-
cellular signal transduction, regulating endothelial cell prolifera-
tion, migration, and angiogenesis. Certain approaches to interfere
with VEGF-induced endothelial cell proliferation, are currently in
preclinical and clinical development, including neutralizing anti-
VEGF monoclonal antibody (8), blocking antibody against VEGFr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
Fig. 1. The structure of CPU-12.
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VEGFR-2 tyrosine kinase (11). Researching and developing new
inhibitor to block the VEGF/VEGFR signal pathway ismeaningful for
anti-angiogenesis and antitumor therapy.
Pyrimidines possess versatile biological activities and are
broadly applied in medical development such as calcium channel
modulator, selective 1-adrenoreceptor antagonist, HIV gpl20-CD4
inhibitor, antiviral, anticancer drug with mitotic kinesin inhibition,
oral antihypertensive, blood platelet aggregation inhibitor,
muscarinic antifungal, and antibacterial drugs (12). Oxazolo[5,4-d]
pyrimidine derivatives are associated with diverse biological ac-
tivities including ricin and shiga toxin inhibition, A2A adenosine
receptor antagonism and kinase inhibition (13e15). These pyrimi-
dine and fused heterocyclic pyrimidine derivatives are of great
biological interest, especially as antiviral, antitumor, antimicrobial,
and anti-inﬂammatory agents.
In our search for potent receptor tyrosine inhibitors, a series of
oxazolo[5,4-d]pyrimidine derivatives were synthesized based on a
computer-assisted drug design protocol (Ya-Hui Dengz, Ji-Ping Liuz,
Yi-Juan Cheng, Yu Liu, Li-Ping Sun, Diarylureas and diarylamides
with oxazolo[5,4-d]pyrimidine scaffold as a novel class of anti-
angiogenesis agents, under submission.). The most promising
compound CPU-12 was selected for biological evaluation in a vir-
tual screen. As shown in Fig. 1, the bicyclic oxazolo[5,4-d]pyrimi-
dine moiety served as a mimic of the adenine ring in ATP to afford
primary afﬁnity between the compound and target kinase and the
amine fragment was intended to exert a hydrophobic interaction
with the target. As an elaborately designed compound, CPU-12may
have inhibitory activity against angiogenesis.
In this study, CPU-12 was further evaluated for antiproliferative
and antiangiogenic activity using various angiogenesis assay
models, both in vitro and ex-vivo. CPU-12 reduced human umbilical
vein endothelial cells (HUVECs) proliferation and migration and
inhibited VEGF-induced tube formation. Meanwhile, CPU-12 was
found to signiﬁcantly inhibit blood capillary-network sprouting in
an ex-vivo rat aortic ring assay model in a dose-dependent manner.
Moreover, the results of western blot analysis indicated that CPU-
12 efﬁciently reduced the phosphorylation of PI3K, ERK1/2 and
p38 MAPK in a dose-dependent manner, while the expression
levels of PI3K, ERK1/2 and p38 MAPK remained unchanged.
2. Materials and methods
2.1. Ethics statement
Animal studies were conducted in conformity with the institu-
tional guide for the care and use of laboratory animal. All rat pro-
tocols were approved by the Animal Care and Use Committee of
China Pharmaceutical University (Nanjing, Jiangsu, China).
2.2. Chemicals and antibodies
DMEM and M199 were purchased from Gibco Life Technologies
(Carlsbad, CA, USA). VEGF was expressed and puriﬁed from
a recombination pichia pastoris. Fetal bovine serum (FBS) was from
Wisent biotechnology Co. Ltd (Nanjing, Jiangsu, China). Matrigel
was purchased from Corning Life Sciences (Corning, NY, USA).
Sources of the antibodies are as follows: PI3K p85/p55 (Ab-467/
199) antibody, ERK1/2 antibody and p38 MAPK (Ab-180/182)
antibody were from Signalway Antibody Inc (College Park, Mary-
land, USA). PI3K p85/p55 (phospho-Tyr467/199) antibody, p44/42
MAPK (Phospho-Thr202/Tyr204) antibody and p38 MAPK (Phos-
pho-Thr180/Tyr182) antibody were obtained from Signalway
Antibody Inc (College Park, Maryland, USA). Goat anti-Rabbit IgG
Secondary Antibody were from Bioworld Technology Inc (Nanjing,Jiangsu, China). The Motic Image Systemwas purchased fromMotic
China group Co. Ltd (Motic Image Plus 2.0, Xiamen, China). In all
experiments, the ﬁnal DMSO concentration was kept <0.1%
throughout the study.
2.3. Cell culture
Human Umbilical Vein Endothelial Cell (HUVEC) were pur-
chased from the American Type Culture Collection (ATCC, Mana-
ssas, VA, USA), and routinely cultured in DMEM containing 10% FBS,
100 mg/ml penicillin and 100 mg/ml streptomycin, maintained in a
humidiﬁed atmosphere of 95% air, 5% CO2 at 37 C. Conﬂuent
HUVECs within 8 passages were used in the experiments described
below.
2.4. Cell proliferation assay
The logarithm phase cells were seeded onto a 96-well plate
(4  103 cells/well) in DMEM containing 10% FBS and incubated for
24 h to produce nearly conﬂuent cell monolayer. Adhered cells
were serum-starved and then treated with CPU-12 (0, 1, 10, 20, 50
and 100 mM) in medium supplemented with 20 ng/ml VEGF for
72 h. After incubation, an MTT assay was used to assess the drug
effects on cell viability (16).
2.5. Cell cycle and apoptosis analysis
HUVECs were plated in 6-well plates at 3  105 cells/well and
allowed to adhere for 24 h. After serum starvation, HUVECs were
activated with 20 ng/ml VEGF for 30min, and then cells were either
incubated in fresh medium alone or supplemented with different
concentration of CPU-12 (2.5, 5, and 10 mM) for an additional 48 h.
The FITC Annexin V Apoptosis Detection Kit (BD, NJ, USA) was
used for the detection of all the stages of apoptosis according to the
manufacturer's instructions. Brieﬂy, HUVECs were harvested after
trypsin treatment and washed with cold phosphate buffered saline
(PBS) and then resuspended in 1  Binding Buffer at a concentra-
tion of 1  106 cells/ml. 100 ml of the solution (1  105 cells) were
transferred to a 5 ml culture tube and then 5 ml of Annexin V and
5 ml Propidium Iodide Staining Solution were added to the solution
for 15 min at room temperature (25 C) and kept in dark place.
Additional 400 ml of 1 Binding Buffer was introduced to each tube
and later cell apoptosis were analyzed by ﬂow cytometry (BD LSRII
System, BD Biosciences, San Jose, CA). The results were analyzed
using FlowJo software (Tree Star, Inc., Asland, USA).
For the cell cycle analysis, after compound treatment, cells were
harvested after trypsin treatment and washed with phosphate
buffered saline (PBS). HUVECs were ﬁxed in precooled 70% ethanol
for 12 h, washed, and resuspended in 1 ml PBS; treated with 10 ml
RNase A; and stained with 5 ml Propidium Iodide at 0.25 mg/ml for
30 min at room temperature, and kept in dark place. The stained
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quantiﬁed using Modiﬁed software (Verity Software House, Inc.,
Topsham, USA).
2.6. Endothelial cell migration assay (wound healing assay)
HUVEC migration was evaluated using a scratch wound healing
assay. HUVECs were cultured in a 6-well plate to form a monolayer.
The cell monolayer was wounded with a 1 mm-wide lane per well
followed with a gentle wash with PBS; cells were supplied with
2 ml medium plus 1% FBS with or without CPU-12 at various con-
centrations (0.1, 1 and 10 mM). The extent of wound closure was
observed and photographed at 0 h, 24 h and 48 h using an inverted
phase-contrast microscope. Images of the denuded endothelial
monolayer were captured using aMotic Image System. The effect of
CPU-12 on the progression of endothelial cell migration was
quantitated by calculating the difference in the denuded area after
48 h. Data were expressed as a percentage of the migration of
untreated endothelial cells groups (mean ± SD).
2.7. Boyden chamber assay of chemotactic endothelial cell invasion
The invasion assay measures the ability of cells to attach to the
matrixes, invade into and through the matrix, and to migrate to-
ward a chemoattractant (17). The transwell chamber migration
system enables to select inhibitors, which may alter the invasive
phenotype of the endothelial cells (18). The bottom surface of the
entire ﬁlter was coated with the diluted Matrigel solution as bar-
riers, leaving the Matrigel layer to air-dry for 30 min. HUVECs were
collected and suspended at a ﬁnal concentration of 2  105 cells/ml
in DMEMmedium containing 1% FBS plus various concentrations of
CPU-12 (0, 0.1, 1 and 10 mM). Fresh DMEM medium with 10% FBS
and 20 ng/ml VEGF were added into the bottom well of the
chamber. After 24 h incubation (at 37 C and 5% CO2), HUVECs were
ﬁxed and stained with Hematoxylin solution. The noninvading cells
were removed from the upper surface of the membrane by
“scrubbing” with a sterile cotton swab. The degree of invaded cells
was quantiﬁed by manual counting, and ﬁve random chosen ﬁelds
were photographed from each group.
2.8. Tube formation assay
When plated on Matrigel, HUVEC spontaneously form capillary-
like tube structures in the presence of serum and endothelial cell
growth supplement. This method can be used to assess compounds
that either inhibit or stimulate angiogenesis (19). Brieﬂy, the pre-
cooled 96-well plates were coated with 60 ml thawed Matrigel for
30min. The logarithm phase cells were harvested and suspended in
DMEM medium containing 10% FBS and VEGF (20 ng/ml). HUVECs
were seeded on coated plates at 5  104 cells/well and treated with
CPU-12 at various concentrations (0, 2.5, 5, and 10 mM) and further
incubated for 8 h. The formed endothelial tubes were photo-
graphed and quantiﬁed. The degree of tube formationwas assessed
by manual counting of the number of tubes in ﬁve random chosen
ﬁelds from each well.
2.9. Rat aortic ring assay
An additional evidence showing the potential activity of CPU-12
to inhibit angiogenesis is provided by the ex-vivo model of the rat
aortic ring assay. The rat aortic ring assay was performed as pre-
viously described (20, 21). Young and 6-week-old male Spra-
gueeDawley rats were anesthetized with pentobarbital and then
humanely sacriﬁced. The entire length of the thoracic and
abdominal aorta was surgically excised and removed from thesacriﬁced rat, using sterile dissecting instruments. The excised
aorta was transferred into a culture dish containing fresh M199
medium and the surrounding ﬁbroadipose tissues were removed.
The proximal and distal 2-mm segments of the aortawere cut away
and were sectioned into 1 mm long ring sections after being rinsed
in 5e8 washes of M199 medium. Care was ensured for the removal
of the remaining blood residues. Then the clotting ﬁbrinogen so-
lution was added into the wells of a 24-well tissue culture plate
before these rings were seeded in 24-well plates for clotting. The
clotting ﬁbrinogen solution contained M199 medium plus 0.3%
ﬁbrinogen and 0.5% 6-aminocaproic acid supplemented with
penicillin and streptomycin. After the ﬁbrin clot formation for
30min, an equal volume of growthmedia (M199medium plus 0.5%
6-aminocaproic acid and 10% FBS) containing various concentra-
tions of CPU-12 (0, 2.5, 5 and 10 mM)was added to eachwell and the
whole was incubated at 37 C with 5% CO2 and the treatment
growth media was removed and changed every 2 days for a total of
8 days. The cultures were stained with MTT and the length and
density of new growth microvessels quantiﬁed and photographed.
For each group, ﬁve ﬁelds were chosen randomly in eachwell of the
replicates, and the inhibition degree of CPU-12 was assessed by
manual counting of the number of new microvessels.
The use of animals was in accordance with the guidelines
established by the National Science Council of The People's Re-
public of China, with adherence to the ethical guidelines for the
care and use of animals.
2.10. Western blot analysis
In order to explore the phosphorylation of a key protein in
VEGF/VEGFR signal pathway, HUVECs were serum starved over-
night and then pre-treated with VEGF (20 ng/ml) for 15 min and
treated with or without various concentrations of CPU-12 (2.5, 5,
and 10 mM). Cells were washed with cold PBS twice and lysed using
RIPA Lysis Buffer (Beyotime Biotechnology, Jiangsu, China) con-
taining protease inhibitors (sodium orthovanadate, sodium ﬂuo-
ride, EDTA, PMSF) and lysates were clariﬁed by centrifugation at
4 C for 10 min at 13,000  g. The concentration of protein in the
supernatants was measured by the BCA Assay Kit. Then equal
amounts of protein (25 mg) were separated by 10% SDS-PAGE and
transferred onto the PVDF membranes (Bio-rad). The blots were
incubated for 12 h in 4 C with anti-Phospho speciﬁc PI3K, ERK1/2,
p38 MAPK antibodies or anti-PI3K, ERK1/2, p38 MAPK antibodies,
followed by horseradish peroxidase (HRP)-conjugated secondary
antibodies (1:5000) for 1 h. Then blots were developed with
enhanced chemiluminescence reagent. All blots were stripped and
reprobed with polyclonal anti-b-actin antibody to ascertain equal
loading of proteins. The densitometric analyses were determined
by using ImageJ software (NIH, Bethesda, MD, USA).
2.11. Statistical analysis
The data were presented as the means ± S.D. using GraphPad
Prism 5.0 software. All experiments were repeated at least three
independent times. The statistical analysis was performed using a
two-tailed Student's t-test using Microsoft Excel software (Micro-
soft Corporation, DC, USA) to calculate differences between groups.
A *P value less than 0.05 was considered signiﬁcant.
3. Result
3.1. CPU-12 inhibits the proliferation of HUVECs
Anti-proliferative activity against HUVECs was determined by a
normal method i.e. the MTT assay as previously described (16). We
Fig. 2. CPU-12 inhibited cell proliferation of VEGF-stimulated HUVEC in a dose-
dependent manner. Attached cells were treated with various concentrations (0, 1, 10,
20, 50 and 100 mM) of CPU-12 for 72 h. Cell survival was quantiﬁed by MTT assay. Cells
receiving 0.1% DMSO and the same concentration of VEGF (20 ng/ml) served as
negative control. Data shown were expressed as means ± S.D. The values represented
are relative to the negative control. ***P < 0.001 versus control, n ¼ 5 per group.
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in vitro. CPU-12 evidently inhibited the proliferation of HUVECs in a
dose-dependent manner (Fig. 2). IC50 values were calculated from a
linear regression curve using Graphpad prism software. HUVECs
were sensitive to CPU-12 treatment with an IC50 value at
9.30 ± 1.24 mM.
3.2. CPU-12 has no prominent inﬂuence on cell cycle arrest and
apoptosis at the tested concentration
Cell cycle progression is directly associated with cell prolifera-
tion, so we investigated the inﬂuence of CPU-12 on the progressionFig. 3. CPU-12 can not induce prominent cell cycle arrest and apoptosis at the tested conc
trations (2.5, 5, and 10 mM) of CPU-12 for 48 h and analyzed by ﬂow cytometry. (A) No sign
were treated with various concentrations, while the percentage of cells in G0/G1, S, and G2/
cells population appeared in the CPU-12 treatment groups.of cell cycle. After treatment of HUVECs with or without CPU-12 for
48 h, the percentages of cells in G0/G1, S, and G2/M phages were
assessed. In the cell cycle analysis, CPU-12 had no signiﬁcantly in-
ﬂuence on cell populations respectively in the G0/G1, S, and G2/M
phages compared with negative control group (Fig. 3A). The results
indicated that CPU-12 did not block cell cycle progression.
Apoptosis is a normal process which occurs in both physiologic
and pathologic conditions of tissue homeostasis. Loss of plasma
membrane is one of the earliest certain morphological character-
istics of the cell apoptosis (22). Prominent early-stage and late-
stage apoptotic cells were not observed in the results of ﬂow
cytometry (Fig. 3B). These results indicated that the CPU-12-
induced inhibition on cell proliferation was not relative to an ac-
tivity on apoptosis.3.3. CPU-12 reduces VEGF-stimulated HUVEC migration and
chemotactic invasion
The migration of HUVECs is a key process of angiogenesis. A
wound healing assay was therefore applied to CPU-12 to assess the
ability of HUVEC migration inhibition. In the wound healing assay,
CPU-12 inhibited cell migration in VEGF stimulated HUVECs in a
dose-dependent manner (Fig. 4A). In the negative group, the
HUVECs migrated into the denuded area after 24 h and 48 h in-
cubation. Signiﬁcant inhibition of HUVEC migration into the
wounded area was observed in the CPU-12 treated group. Quanti-
tative analysis revealed that treatment with CPU-12 at 0.1 mM,1 mM,
and 10 mM resulted in 83%, 56% and 22% number of migrated cells in
contrast with the negative group, respectively. These results
demonstrated the potentiality of CPU-12 in inhibiting HUVEC
migration in vitro.entration in HUVEC. The VEGF-stimulated HUVECs were treated with various concen-
iﬁcant cell cycle arrest was observed with the treatment of CPU-12 in HUVEC. HUVECs
M phases were almost the same. (B) No prominent early-stage and late-stage apoptotic
Fig. 4. CPU-12 inhibited VEGF-stimulated HUVEC migration and invasion by a scratch wound healing assay and transwell assay. (A) The cell monolayer were wounded (the wound
was shown between the two yellow lines in each photo) at 0 h, and then treated with various concentrations (0.1, 1, and 10 mM) of CPU-12 after activated with 20 ng/ml VEGF.
Photographs were taken at 0 h, 24 h and 48 h (Magniﬁcation: 100.). Quantiﬁcation of the number of migrated cells (cells between the two yellow lines) was done after 48 h
exposure. Data shown were expressed as means ± S.D. The value represented was relative to control (0 mM). **P < 0.01 and ***P < 0.001 versus control, n ¼ 3 per group. (B) The
bottom surface of the entire ﬁlter was coated with the diluted Matrigel solution, and HUVECs were treated with various concentrations of CPU-12 and suspended in the upper
chamber. Medium in the down chamber contained 20 ng/ml VEGF. After 48 h, the cells on the bottom side of the ﬁlter were ﬁxed, stained and visualized using a microscope
(Magniﬁcation: 100.). Quantitative results of the average number of invasion cells (cells invaded to the lower side of the membrane in the Transwell Chamber) were obtained after
48 h exposure. Data shown were expressed as means ± S.D. The values represented are relative to control (0 mM). *P < 0.05 and **P < 0.01 versus control, n ¼ 3 per group.
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determined by the transwell chamber assay, as previously
described (18). CPU-12 signiﬁcantly inhibited VEGF-stimulated in-
vasion of HUVECs in a dose-dependent manner (Fig. 4B). In the
negative control group, a great quantity of HUVECs invaded from
the upper side to the lower side of the membrane in the Transwell
Chamber. CPU-12 reduced the VEGF-induced invasion at 74%, 62%,
33% over the control at 0.1 mM, 1 mM, 10 mM respectively. These
results demonstrated that CPU-12 could suppress VEGF-induced
invasion of HUVECs in vitro.
3.4. CPU-12 reduces VEGF-stimulated capillary tube formation of
HUVECs
The tube formation assay is based on the differentiation of
HUVECs on the Matrigel. HUVEC differentiate and form capillary-
like structures on Matrigel in the presence of 10% serum and
20 ng/ml VEGF (23). Under these conditions the formation of tube-
like vessels can be used to assess the potential activity of com-
pounds. The scale and density of tube-like structures were effec-
tively reduced by CPU-12 in a dose-dependent manner (Fig. 5).
Fig. 5 showed that a reticular and well-deﬁned tube-like structure
was formed within 8 h in the negative control group. When
HUVECs were exposed to CPU-12, the tube structures were
destroyed depending on the compound concentration. At aconcentration of 10 mMor higher, the morphogenesis of HUVECs on
theMatrigel was evidently inhibited. A partial inhibition of the tube
like structure formation which was unable to form meshes was
observed when HUVECs were treated with lower concentration
(5 mM and 2.5 mM) of CPU-12. Quantitative analysis revealed that
treatment with CPU-12 resulted in 31%, 48%, and 68% inhibition of
VEGF-induced tube formation at 2.5 mM, 5 mM, and 10 mM,
respectively. The interferential tube formation structures and the
distinctive morphological cell characteristics resulted are indicative
of the potential antiangiogenic activity of CPU-12.
3.5. CPU-12 suppresses microvessels sprouting from the rat aortic
ring
The rat aortic ring assay is a valuable method which integrates
the advantages of both in vivo and in vitro systems (24). It is a useful
assay to test inhibitors in a controlled environment, and it contains
the necessary steps involved in angiogenesis (25, 26). In the rat
aortic ring assay early formation of new microvessels was ﬁrst
observed on the fourth day in the negative control group. After
being cultivated for 8 days, the rat aortic ring was able to generate
long and dense new microvessels in the absence of CPU-12. In the
treated groups, the formation of microvessels sprouting from the
explants of rat aortic ring was inhibited in a dose-dependent
manner (Fig. 6). In the group treated with CPU-12 at 2.5 mM, lots
Fig. 5. CPU-12 reduced VEGF-stimulated HUVEC tube formation. The images showed the morphological features of VEGF-stimulated HUVEC on Matrigel in the presence or absence
of various concentrations of CPU-12 for 8 h. (A) Negative control (containing 20 ng/ml VEGF), (B) 2.5 mM CPU-12 plus VEGF, (C) 5 mM CPU-12 plus VEGF, (D) 10 mM CPU-12 plus VEGF.
(Magniﬁcation: 40.). (E) Quantiﬁcation of the number of tubes after 8 h exposure. Data shownwere expressed as means ± S.D. The values represented were relative to the negative
control. *P < 0.05 and **P < 0.01 versus control, n ¼ 3 per group.
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vessels were prominently decreased when treated with 5 mM
versus the negative group. Almost complete inhibition was
observed at the highest concentration of CPU-12 (10 mM).
Compared with the negative group, microvessels sprouting from
the rat aortic ring were found to be signiﬁcantly reduced to 82%,
61%, 29% at concentration of 2.5 mM, 5 mM, and 10 mM respectively.
These results conﬁrmed that the presence of CPU-12 in the aortic
outgrowth has suppressed the process of microvessels sprouting
from the aortic wall ex-vivo.
3.6. Inﬂuence of CPU-12 on VEGFR-2 related pathways in VEGF-
stimulated HUVECs
To understand the molecular mechanism of action of CPU-12 in
VEGF-stimulated HUVECs, we investigated three key proteinsexpression levels in the VEGFR-2 related downstream signaling,
including PI3K, ERK1/2 and p38 MAPK (27). Western blot assays
were used for the detection of both phosphorylated and total
protein levels of PI3K, ERK1/2 and p38 MAPK, which play signiﬁ-
cant role in the VEGFR-2 signal pathway. As shown in the results
below, the phosphorylation level of these critical proteins was
dose-dependently down-regulated in response to the CPU-12
respective treatment groups after the addition of exogenous VEGF
into HUVECs (Fig. 7). The phosphorylation of PI3K, ERK1/2 and p38
MAPK activated by VEGF was effectively inhibited by CPU-12, while
the total protein levels of PI3K, ERK1/2 and p38 MAPK remained
constant. The phosphorylated protein versus total protein values
were calculated in order to show the expression level of phos-
phorylated protein. These results suggest that VEGFR-2 might be a
potential target of CPU-12 leading to interference of VEGF-
stimulated signal transduction.
Fig. 6. CPU-12 suppresses microvessels sprouting from the rat aortic ring. The explants of rat aortic ring were seeded into Matrigel and treated with various concentration of CPU-
12. After further incubation for 8 days, the samples were stained with MTT and visualized using a microscope (Magniﬁcation: 40.). (A) Negative control group, (B) 2.5 mM CPU-12
group, (C) 5 mM CPU-12 group, (D) 10 mM CPU-12 group. (E) The number of new microvessels in each treatment group was quantiﬁed. Data shown were expressed as means ± S.D.
The values represented were relative to the negative control. **P < 0.01 versus control, n ¼ 3 per group.
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Angiogenesis is driven by numerous cells including endothelial
cells, inﬂammatory cells and tumor cells by secreting soluble pro-
angiogenic and anti-angiogenic molecules which control neo-
vascularization (28). Angiogenesis plays a major role in the devel-
opment of pathological diseases, including inﬂammation, cancer,
rheumatic arthritis and arteriosclerosis. Tumors can rarely grow
vigorous and metastasize to other organs without the evolvement
and promotion of new blood vessels (29). In the process of angio-
genesis, many molecules have the capability of inducing the for-
mation of new vessels including angiogenin (30), insulin-like
growth factor I (IGF-1) (31), platelet-derived endothelial cell
growth factor (PDGF) and vascular endothelial growth factor
(VEGF) (32). Among these molecules, VEGF is generally expressed
in many different cell types and angiogenesis-related processes aswell as diseases. Correspondingly, VEGF receptors are expressed in
invading and proliferating endothelial cells and tumor cells. Inter-
fering with the VEGFR-2 signal pathway is promising for anti-
angiogenesis and antitumor therapy.
Oxazolo[5,4-d]pyrimidines have been reported to possess a va-
riety of biological activities including gastric antisecretory activity
(33), kinase inhibition, adenosine receptor antagonism and tumor
growth inhibition. Interest in this ring system has increased due to
recent reports, but the antiangiogenesis activity is barely reported.
We try to demonstrate that the newly synthesized compound, CPU-
12, which possesses the oxazolo[5,4-d]pyrimidine structure, has
potential in inhibiting angiogenesis.
In the inhibition proliferation assay, we found that CPU-12
signiﬁcantly inhibited HUVEC proliferation in a dose-dependent
manner with a relatively low IC50 value. To evaluate whether the
inhibition effect on HUVECs' proliferation by CPU-12was due to cell
Fig. 7. CPU-12 down-regulate the phosphorylation of PI3K, ERK1/2, and p38 MAPK, and the total steady state remained constant in endothelial cells. Serum-starved HUVECs were
activated with VEGF (20 ng/ml) and then treated with or without CPU-12 (0, 2.5, 5, and 10 mM) for 1 h. (A) Protein expression levels of phosphorylated PI3K, ERK1/2, p38 MAPK and
total PI3K, ERK1/2, p38 MAPK were analyzed by western blot and normalized with the b-actin. (B), (C) and (D) Representative the densitometric analyses of the expression ratio of
p-PI3K vs total PI3K, p-ERK1/2 vs total ERK1/2 and p-p38 MAPK vs total p38 MAPK. Data shown were expressed as means ± S.D. The values represented were relative to control
(0 mM). *P < 0.05, **P < 0.01 and ***P < 0.001 versus control, n ¼ 3 per group.
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were assessed by ﬂow cytometry. As the results shown, no prom-
inent early-stage and late-stage apoptotic cells were observed in
the dot plot of ﬂow cytometry. It indicated that the CPU-12-induced
inhibition proliferative effect was not due to its apoptosis activity.
The possible mechanism for CPU-12 to inhibit the HUVEC prolif-
eration is related to the inﬂuence of receptor tyrosine kinase, which
agrees with the drug design.
To determine the antiangiogenic activity of CPU-12, we per-
formed several antiangiogenesis experiments in VEGF-stimulated
HUVEC in vitro, including cell migration, invasion and tube for-
mation assay. The results of scratch wound healing assays and
transwell assay showed that CPU-12 was capable to inhibit the
motility of HUVECs. The tube formation assay is based on the dif-
ferentiation of HUVECs on a basement membrane matrix. The re-
sults showed that CPU-12 disturbed the formation of capillary-like
structures. It can be inferred that CPU-12 may affect the differen-
tiation of HUVECs and reduce the tube formation.
Several assays are available to assess angiogenesis in vitro and
in vivo. Assays in vivo can stimulate the natural process but are
often complicated by the recruitment or stimulation of tissue cell
which in turn release angiogenic factors that may interfere with
angiogenesis (34), while variables of assays in vitro are more likely
to be controlled. We use ex-vivo experiments to evaluate the direct
effects of compounds on the vascular cells. The rat aortic ring assay,
developed by Nicosia et al., can integrate the advantages of both
in vitro and in vivo system. It recapitulates the necessary step
involved in angiogenesis and can test angiogenic factors orinhibitors in a controlled environment. The results of the rat aortic
ring assay showed that the density and length of new microvessels
were inhibited by CPU-12. This ex-vivo assay conﬁrmed that CPU-
12 inhibited the nature process of angiogenesis. In our future
study, various angiogenesis assay models in vivo will be used for
further biological proﬁling.
Vascular endothelial growth factor receptor were formed both
homodimers and heterodimers and were accompanied with the
autophosphorylation state, by binding with the proper ligand (35).
Phosphorylated receptors recruit interacting proteins and induce
the activation of signaling pathways that involve a series of second
messengers. In the VEGF/VEGFR-2 pathway, the function of ERK1/2
are known to regulate the cell proliferation.While the PI3K and p38
MAPK are associated with cell survival, vascular permeability and
cell migration (36e39). Western blot analysis was performed to
evaluate the molecular mechanism of CPU-12 against VEGF-
stimulated angiogenesis in HUVEC. Results indicated that the
phosphorylation of PI3K, ERK1/2 and p38 MAPK were effectively
inhibited by CPU-12, while the total protein levels of PI3K, ERK1/2
and p38 MAPK remained constant. These decreases of the phos-
phorylated protein expression level, especially the phosphorylation
of PI3K, suggested that CPU-12 might be a potent inhibitor of the
VEGFR-2 tyrosine kinase.
In conclusion, the oxazolo[5,4-d]pyrimidine derivative, CPU-12
was able to inhibit VEGF-stimulated HUVEC proliferation, migra-
tion, invasion and tube formation. We demonstrated that CPU-12
suppressed microvessels sprouting from the rat aortic ring and
reduce the phosphorylation of PI3K, ERK1/2 and p38 MAPK
J. Liu et al. / Journal of Pharmacological Sciences 129 (2015) 9e17 17expression level. We demonstrated that oxazolo[5,4-d]pyrimidine
derivatives inhibited angiogenesis in vivo and ex-vivo for the ﬁrst
time. These results further suggest that oxazolo[5,4-d]pyrimidine
derivatives and similar analogs may be excellent leads in the
development of anti-angiogenic and anti-cancer drugs.
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